KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Elanco Animal Health (ELAN) Revenue (2017 - 2025)

Historic Revenue for Elanco Animal Health (ELAN) over the last 9 years, with Q3 2025 value amounting to $1.1 billion.

  • Elanco Animal Health's Revenue rose 1038.83% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year increase of 307.59%. This contributed to the annual value of $4.4 billion for FY2024, which is 49.81% up from last year.
  • Per Elanco Animal Health's latest filing, its Revenue stood at $1.1 billion for Q3 2025, which was up 1038.83% from $1.2 billion recorded in Q2 2025.
  • Elanco Animal Health's 5-year Revenue high stood at $1.3 billion for Q2 2021, and its period low was $985.0 million during Q4 2022.
  • Over the past 5 years, Elanco Animal Health's median Revenue value was $1.1 billion (recorded in 2025), while the average stood at $1.1 billion.
  • Per our database at Business Quant, Elanco Animal Health's Revenue skyrocketed by 11808.87% in 2021 and then tumbled by 1142.09% in 2022.
  • Over the past 5 years, Elanco Animal Health's Revenue (Quarter) stood at $1.1 billion in 2021, then decreased by 11.42% to $985.0 million in 2022, then increased by 5.08% to $1.0 billion in 2023, then dropped by 1.45% to $1.0 billion in 2024, then rose by 11.47% to $1.1 billion in 2025.
  • Its Revenue stands at $1.1 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.2 billion for Q1 2025.